Hydrocortisone inhibition of the bradykinin activation of human synovial fibroblasts.
Human synovial fibroblasts in culture respond to bradykinin with a 20-fold increment in intracellular cyclic AMP concentrations, however bradykinin does not directly activate adenylate cyclase activity in a particulate fraction derived from these cells. Bradykinin evokes a release of labeled arachidonic acid and prostaglandins E and F from synovial fibroblasts pre-labeled with 3H-arachidonic acid. Hydrocortisone inhibits the bradykinin induced increment in cyclic AMP and the release of arachidonic acid and prostaglandins E and F from synovial fibroblasts. Indomethacin, which also inhibits the cyclic AMP response to bradykinin, has no effect on the release of arachidonic acid from synovial fibroblasts. Indomethacin does, however, inhibit the quantity of prostaglandins released into the medium. These studies support the hypothesis that bradykinin does not activate human synovial fibroblast adenylate cyclase, but presumably activates a phospholipase whose products in turn result in the synthesis of prostaglandins. These and other investigations also suggest that a product(s) of the prostaglandin pathway causes the increment in cyclic AMP.
D000262:Adenylyl Cyclases / Q000378:metabolism*; D001095:Arachidonic Acids / Q000378:metabolism; D001920:Bradykinin / Q000037:antagonists & inhibitors*; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism*; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000494:pharmacology*; D007213:Indomethacin / Q000494:pharmacology; D011458:Prostaglandins E / Q000378:metabolism; D011460:Prostaglandins F / Q000378:metabolism; D013583:Synovial Membrane / Q000166:cytology*
D001095:Arachidonic Acids; D011458:Prostaglandins E; D011460:Prostaglandins F; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D001920:Bradykinin; D006854:Hydrocortisone; D007213:Indomethacin